+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products

Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products

European Journal of Pharmaceutics and Biopharmaceutics 107: 223-233

The aim of this study was to incorporate an optimized RPMI2650 nasal cell model into a 3D printed model of the nose to test deposition and permeation of drugs intended for use in the nose. The nasal cell model was optimized for barrier properties in terms of permeation marker and mucus production. RT-qPCR was used to determine the xenobiotic transporter gene expression of RPMI 2650 cells in comparison with primary nasal cells. After 14days in culture, the cells were shown to produce mucus, and to express TEER (define) values and sodium fluorescein permeability consistent with values reported for excised human nasal mucosa. In addition, good correlation was found between RPMI 2650 and primary nasal cell transporter expression values. The purpose-built 3D printed model of the nose takes the form of an expansion chamber with inserts for cells and an orifice for insertion of a spray drug delivery device. This model was validated against the FDA glass chamber with cascade impactors that is currently approved for studies of nasal products. No differences were found between the two apparatus. The apparatus including the nasal cell model was used to test a commercial nasal product containing budesonide (Rhinocort, AstraZeneca, Australia). Drug deposition and transport studies on RPMI 2650 were successfully performed. The new 3D printed apparatus that incorporates cells can be used as valid in vitro model to test nasal products in conditions that mimic the delivery from nasal devices in real life conditions.

(PDF emailed within 0-6 h: $19.90)

Accession: 057221773

Download citation: RISBibTeXText

PMID: 27418393

DOI: 10.1016/j.ejpb.2016.07.010

Related references

RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. European Journal of Pharmaceutics and Biopharmaceutics 74(2): 290-297, 2010

Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. Journal of Pharmaceutical Sciences 97(3): 1165-1178, 2007

The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model. Pharmaceutical Research 32(2): 665-679, 2015

Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?. European Journal of Drug Metabolism and Pharmacokinetics, 2017

Evaluation of the human cell line RPMI 2650 as an in vitro nasal model. Rhinology 33(4): 194-198, 1995

Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. Journal of Pharmacy and Pharmacology 64(11): 1621-1630, 2013

The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor-beta gene expression and protein release. Clinical and Experimental Allergy 35(6): 811-819, 2005

Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. Cytotechnology 65(3): 395-406, 2012

Activity of Multidrug Resistance-Associated Proteins 1-5 (MRP1-5) in the RPMI 2650 Cell Line and Explants of Human Nasal Turbinate. Molecular Pharmaceutics 14(5): 1577-1590, 2017

Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells. Molecules 21(5): -, 2016

Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells. International Journal of Pharmaceutics 508(1-2): 22-33, 2016

Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells. European Journal of Pharmaceutical Sciences, 2018

Personalized medicine in nasal delivery: the use of patient-specific administration parameters to improve nasal drug targeting using 3D printed nasal replica casts. Molecular Pharmaceutics, 2018

Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs. International Journal of Pharmaceutics 515(1-2): 1-10, 2016

Roles of epidermal growth factor receptor signaling pathway on cultured human nasal epithelial cells RPMI-2650. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 44(3): 203-208, 2011